Ischemia
reperfusion injury is a medical condition which involves tissue injury, resulting in the interruption
of blood supply, and occurs when the blood supply to an area of tissue is cut
off. Ischemia-related tissue injury can occur in various organs including heart
and brain.
Access
Detailed Report Summary:
During
reperfusion injury, inflammatory responses occur including release of free
radicals, vascular leakage, recruitment of inflammatory cells, and proteins
that cause tissue destruction. Currently there are no available drug therapies
but surgeries are available to remove the blood clot responsible for restricted
blood flow.
Request
to Get the Sample Pages at:
Radikal
Therapeutics is in the process of developing R-190 as a new chemical entity for
the treatment of limb ischemia reperfusion injury. Some of the companies having
a pipeline of ischemia reperfusion injury include Catalyst Biosciences Inc. and
NovelMed Therapeutics Inc. among others.
The report
provides a comprehensive understanding of the pipeline activities covering all
drug candidates under various stages of development, with the detailed analysis
of pipeline and clinical trials.
Pipeline
analysis of drugs by phases includes product description and development
activities including information about clinical results, designations,
collaborations, licensing, grants, technology, and others.
No comments:
Post a Comment